Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 115Carcinoma, Non-Small-Cell Lung 103Prostatic Neoplasms 90Neoplasms 74Multiple Myeloma 73Lung Neoplasms 64Colorectal Neoplasms 50Leukemia, Myeloid, Acute 46Neoplasm Metastasis 43Lymphoma 39Pancreatic Neoplasms 38Melanoma 38Lymphoma, Non-Hodgkin 36Carcinoma, Renal Cell 36Ovarian Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Squamous Cell Carcinoma of Head and Neck 31Urinary Bladder Neoplasms 30Hematologic Neoplasms 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Endometrial Neoplasms 26Uterine Cervical Neoplasms 25Carcinoma, Hepatocellular 25Triple Negative Breast Neoplasms 24Sarcoma 24Glioma 24Stomach Neoplasms 22Head and Neck Neoplasms 22Lymphoma, Large B-Cell, Diffuse 21Brain Neoplasms 21

Interventions

cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Non-small Cell Lung Cancer × 30 days × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Regeneron Pharmaceuticals

Active not recruiting
1,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡